Large-cap Health Care company Teva Pharmaceutical Industries has moved 0.5% so far today on a volume of 3,648,913, compared to its average of 14,549,725. In contrast, the S&P 500 index moved -1.0%.
Teva Pharmaceutical Industries trades -4.3% away from its average analyst target price of $10.11 per share. The 9 analysts following the stock have set target prices ranging from $8.0 to $14.0, and on average have given Teva Pharmaceutical Industries a rating of hold.
Anyone interested in buying TEVA should be aware of the facts below:
-
Teva Pharmaceutical Industries has moved -12.0% over the last year, and the S&P 500 logged a change of 10.0%
-
Based on its trailing earnings per share of -1.42, Teva Pharmaceutical Industries has a trailing 12 month Price to Earnings (P/E) ratio of -6.8 while the S&P 500 average is 15.97
-
TEVA has a forward P/E ratio of 3.9 based on its forward 12 month price to earnings (EPS) of $2.46 per share
-
The company has a price to earnings growth (PEG) ratio of 2.63 — a number near or below 1 signifying that Teva Pharmaceutical Industries is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 1.54 compared to its sector average of 4.16
-
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
-
Based in Tel Aviv, the company has 34,004 full time employees and a market cap of $11.15 Billion.